直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
Charles T. Collins-Chase
Partner
More
vCard
  • 901 New York Avenue, NW
  • Washington, DC 20001-4413
+1 202 408 4108
charles.collins-chase@finnegan.com charles.collins-chase@finnegan.com

Charles T. Collins-Chase

Partner

  • +1 202 408 4108 +1 202 408 4108
  • charles.collins-chase@finnegan.com charles.collins-chase@finnegan.com
  • 901 New York Avenue, NW
  • Washington, DC 20001-4413
  • vCard

Charles Collins-Chase, co-leader of Finnegan’s Appeals, Issues, and Legal Strategy Section, focuses on district court patent litigation and appeals before the U.S. Court of Appeals for the Federal Circuit, where he served as a clerk. He is a first-chair litigator who has handled cases at every stage, from pre-litigation through discovery, dispositive motions, and trial. In the courtroom, Charles has argued at Markman hearings, examined key expert witnesses, argued judgement as a matter of law (JMOL) and other motions, and given openings.

Charles uses his chemical engineering background to support clients in protecting their innovations across a wide range of technologies, including pharmaceuticals and biotechnologies, energy and renewables, and chemical products. He has assisted numerous clients in Hatch-Waxman (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) litigations. Charles also counsels clients on using artificial intelligence (AI) and machine learning (ML) systems for drug discovery and development.

 

Charles has extensive experience at the Federal Circuit, where he has argued cases and assisted clients in more than thirty appeals from decisions by district courts and the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO). He has particular insight into appeals involving patent eligibility under 35 U.S.C. § 101, having represented the petitioners in Bilski v. Kappos before the U.S. Supreme Court.

 

Charles also has substantial experience representing clients in post-grant proceedings at the PTAB. In his roles as lead inter partes review (IPR) counsel, he has deposed and defended key experts witnesses and inventors, drafted petitions and patent owner responses, and argued at oral hearings.

 

With broad expertise in clean energy and renewable technologies, Charles has handled litigation, appeals, and due diligence matters involving technologies ranging from renewable diesel fuel and biofuels to pollution control systems and biobased polymers. Before law school, Charles completed an M.Phil. in engineering for sustainable development at the University of Cambridge, where he researched the feasibility of community-scale biodiesel production using a novel reactor system. His undergraduate thesis research involved synthesizing and characterizing thermosetting polymers made from soybean oil and other renewable resources.

 

Charles devotes substantial time to pro bono matters and has served as the leader of the firm’s pro bono committee. He argues before the Federal Circuit on behalf of veterans seeking service-connected disability benefits.

 

Et Cetera

  • Capital Pro Bono Honor Roll, 2016, 2018-2020; High Honor Roll, 2016, 2020.
  • Law clerk to the Honorable Kimberly A. Moore at the U.S. Court of Appeals for the Federal Circuit, 2011-2013.

Experience

Bial - Portela & CA S.A. v. Alkem Laboratories Ltd et al.

Represented Bial in district court Hatch-Waxman litigation involving the anti-epileptic drug Aptiom®.

1:18-cv-00304, D. Del., Judges Connolly, Burke

Bay Materials, LLC v. 3M Company

Representing Bay Materials, LLC in district court patent litigation involving multilayer polymer sheet material used in clear dental aligners.

1:21-cv-01610, D. Del., Judges Andrews, Hall

AbbVie Inc. et al v. Alvotech hf.

Represented AbbVie Inc. in Biologics Price Competition and Innovation (BPCIA) litigation related to Humira®

1:21-cv-02258, 1:21-cv-02899, N.D. Ill., Judge Lee

Daicel Corporation v. Celanese International Corp.

Successfully represented Celanese International Corp. as lead counsel in two Federal Circuit appeals from IPR proceedings involving industrial acetic acid production, obtaining affirmance of the PTAB’s rulings in Celanese’s favor.

18-2130, -2131, Fed. Cir.

E. I. du Pont de Nemours v. Synvina C.V.

Represented DuPont and ADM in a successful Federal Circuit appeal from an IPR proceeding, resulting in reversal of the PTAB’s decision and invalidation of all challenged claims of Synvina’s patent directed to production of 2,5-furan dicarboxylic acid.

17-1977, Fed. Cir.

Dialware Communications, LLC v. Hasbro, Inc.

Lead counsel for Dialware Communications in a Federal Circuit appeal from a district court decision invalidating five patents under 35 U.S.C. § 101.

17-1952, Fed. Cir.

More

Insights

Articles

Skinny Labels, Larger Risks: Supreme Court Considers Induced Infringement Standards in Hikma v. Amarin

Skinny Labels, Larger Risks: Supreme Court Considers Induced Infringement Standards in Hikma v. Amarin Skinny Labels, Larger Risks: Supreme Court Considers Induced Infringement Standards in Hikma v. Amarin

March 3, 2026

Westlaw Today

Articles

Artificial Intelligence IP Protection Needs Updated Approaches

Artificial Intelligence IP Protection Needs Updated Approaches Artificial Intelligence IP Protection Needs Updated Approaches

April 22, 2025

Bloomberg Law

Seminar

Intellectual Property in the Age of AI: What Do You Own and How Do You Balance Risks? Intellectual Property in the Age of AI: What Do You Own and How Do You Balance Risks?

September 25, 2024

Boston

Articles

Regulation and Legislation in the Era of Automation and Digitalisation

Regulation and Legislation in the Era of Automation and Digitalisation Regulation and Legislation in the Era of Automation and Digitalisation

June 7, 2024

European Pharmaceutical Review

Conference

Pharma & Biotech Patent Litigation Europe 2024 Pharma & Biotech Patent Litigation Europe 2024

January 22-24, 2024

Amsterdam

Articles

The Future of AI in the Pharmaceutical Industry

The Future of AI in the Pharmaceutical Industry The Future of AI in the Pharmaceutical Industry

April 27, 2023

European Pharmaceutical Manufacturer
More

News

Commentary

Justices to Side with Generic Drugmakers in Patent Spat, Attorneys Predict Justices to Side with Generic Drugmakers in Patent Spat, Attorneys Predict

May 5, 2026

Westlaw Today

Commentary

Supreme Court Takes Up Generic Drug Labeling Fight Supreme Court Takes Up Generic Drug Labeling Fight

April 29, 2026

Axios

Commentary

The Topics Appellate Attys Are Tracking Most Closely in 2026 The Topics Appellate Attys Are Tracking Most Closely in 2026

January 2, 2026

Law360

Press Release

Finnegan Exceeds $3M in Donations to DAV Finnegan Exceeds $3M in Donations to DAV

February 13, 2025

Press Release

46 Finnegan Attorneys Named to 2021 Capital Pro Bono Honor Roll 46 Finnegan Attorneys Named to 2021 Capital Pro Bono Honor Roll

June 3, 2022

Commentary

Finnegan Taps Its Federal Circuit Chops for Military Vets in Disability Cases Finnegan Taps Its Federal Circuit Chops for Military Vets in Disability Cases

August 16, 2021

The AmLaw Litigation Daily
More

Professional Activities

  • Federal Circuit Bar Association
  • Maryland Bar Association
  • American Institute of Chemical Engineers (AIChE)
    (chair of Chemical Engineering and the Law Forum)
  • District of Columbia Bar
Admissions and Education

Admissions

  • U.S. Patent and Trademark Office
  • District of Columbia
  • Maryland
  • U.S. Court of Appeals, Federal Circuit

Education

University of Pennsylvania Law School
J.D., cum laude, 2008
University of Cambridge (Cambridge-MIT Institute)
M.Phil., Engineering for Sustainable Development, with distinction, 2005
University of Delaware
B.S., Chemical Engineering, Honors Degree with Distinction, cum laude, 2004

Clerkships

  • U.S. Court of Appeals, Federal Circuit, Hon. Kimberly A. Moore

Charles's Practices

AI + Finnegan
AI + Patent
AI + Trade Secrets
Appeals, Issues, and Legal Strategy
Appeals from the PTAB
Federal Circuit and Supreme Court Appeals
Global IP Enforcement, Litigation, and Trials
Branded Hatch-Waxman (ANDA) Litigation and Trials
Federal Circuit and Supreme Court Appeals
Patent Litigation and Trials
Pretrial Strategies
Trade Secrets
Patent Office Invalidation Proceedings
Ex Parte Reexamination (EPR)
PTAB Invalidation Proceedings: IPR and PGR
Prosecution and Portfolio Management
Due Diligence
Ex Parte Reexamination (EPR)
IP Portfolio Management
Opinions and Counseling
Trade Secrets

Charles's Industries

AI, Electronics, and Information Technology
Artificial Intelligence (AI) and Machine Learning (ML)
Chemicals, Industrials, and Materials
Chemical
Communications
Financial Services and Business Systems
Energy
Clean Energy and Renewables
Oil and Gas
Life Sciences
Biologics
Biotechnology
Pharmaceutical

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP